Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Human neutralizing human immunodeficiency virus type 2-specific Fab molecules generated by phage display.

Ewa Björling1,2, Eva von Garrelts3, Andreas Mörner1,2

  • 1Department of Immunology, Microbiology, Pathology and Infectious Diseases (IMPI), Karolinska Institute, Huddinge, Sweden2.

The Journal of General Virology
|August 31, 1999
PubMed
Summary

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

An ultra-long heavy chain bovine antibody neutralizes SARS-CoV-2 and reacts broadly with sarbecoviruses.

bioRxiv : the preprint server for biology·2025
Same author

bioRxiv : the preprint server for biology·2023
Same author

Development and characterization of a human monoclonal antibody targeting the N-terminal region of hepatitis C virus envelope glycoprotein E1.

Virology·2017
Same author

Production of individualized V gene databases reveals high levels of immunoglobulin genetic diversity.

Nature communications·2016
Same author

Humoral response to influenza vaccination in relation to pre-vaccination antibody titres, vaccination history, cytomegalovirus serostatus and CD4/CD8 ratio.

Infectious diseases (London, England)·2016
Same author

A Diverse Panel of Hepatitis C Virus Glycoproteins for Use in Vaccine Research Reveals Extremes of Monoclonal Antibody Neutralization Resistance.

Journal of virology·2015

Researchers generated human immunodeficiency virus type 2 (HIV-2)-neutralizing Fab fragments using phage display. These fragments show potential for HIV-2 vaccine design and therapeutic applications.

Area of Science:

  • Immunology
  • Virology
  • Biotechnology

Background:

  • Human immunodeficiency virus type 2 (HIV-2) remains a public health concern.
  • Developing effective neutralizing antibodies against HIV-2 is crucial for therapeutic and prophylactic strategies.
  • Recombinant antibody fragments offer versatile tools for studying viral antigens and developing interventions.

Purpose of the Study:

  • To generate and characterize human immunodeficiency virus type 2 (HIV-2)-neutralizing recombinant Fab fragments.
  • To assess the neutralizing capacity of these fragments against HIV-2 envelope glycoprotein (gp125).
  • To explore the potential applications of these Fab fragments in HIV-2 research, vaccine design, and therapy.

Main Methods:

  • Phage display technique was employed to construct a combinatorial library from an HIV-2-seropositive individual.

Related Experiment Videos

  • The library was screened against native HIV-2 envelope glycoprotein (gp125).
  • Enzyme-linked immunosorbent assay (ELISA) and sequencing of heavy chain CDR3 regions were used for characterization.

    • Main Results:

    • Ten of 30 generated Fab fragments showed strong reactivity to gp125 in ELISA.
    • Six Fab fragments demonstrated neutralizing capacity against a homologous HIV-2 strain (titres 20-80).
    • One Fab fragment exhibited weak neutralization against a heterologous HIV-2 isolate (K135).

    Conclusions:

    • Generated Fab fragments are specific for HIV-2 gp125 and possess neutralizing activity.
    • These reagents can aid in understanding HIV-2 envelope antigen structure and immunogenicity, informing vaccine development.
    • Cloned Fab genes hold promise for therapeutic and immunoprophylactic applications, including potential human use.